These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 12168866)

  • 41. Serum levels of CA 125 and TPS during treatment of ovarian cancer.
    Van Dalen A; Favier J; Baumgartner L; Hasholzner U; De Bruijn H; Dobbler D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Anticancer Res; 2000; 20(6D):5107-8. PubMed ID: 11326677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
    Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
    Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer.
    Simojoki M; Santala M; Risteli J; Kauppila A
    Gynecol Oncol; 2001 Jul; 82(1):110-5. PubMed ID: 11426971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer.
    Oehler MK; Caffier H
    Anticancer Res; 2000; 20(6D):5109-12. PubMed ID: 11326678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [-CA-125 antigen as a prognostic factor for survival in patients with epithelial ovarian carcinoma of FIGO stage I--preliminary results-].
    Nagele E; Kurz C; Speiser P; Vavra N; Sevelda P
    Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):79-82. PubMed ID: 8647363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Tate S; Hirai Y; Takeshima N; Hasumi K
    Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
    Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
    Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
    Riedinger JM
    Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI.
    Kim HS; Kim JW; Cho JY; Chung HH; Park NH; Song YS; Kim SH; Kang SB
    Eur J Surg Oncol; 2009 Aug; 35(8):870-6. PubMed ID: 19179039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A new prognostic model for FIGO stage 1 epithelial ovarian cancer.
    Obermair A; Fuller A; Lopez-Varela E; van Gorp T; Vergote I; Eaton L; Fowler J; Quinn M; Hammond I; Marsden D; Proietto A; Carter J; Davy M; Tripcony L; Abu-Rustum N
    Gynecol Oncol; 2007 Mar; 104(3):607-11. PubMed ID: 17092548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H; Duranyildiz D; Tas F; Yasasever V
    Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.